lobbying_activities: 3438019

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3438019	b06aa48c-4220-4401-b6cb-95f10234db6e	Q3	DLA PIPER LLP (US)	76855	BIOTECHNOLOGY INNOVATION ORGANIZATION	2025	third_quarter	PHA	340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.	Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE	60000		0	0	2025-10-16T16:24:37-04:00